Concise Review: Towards the Clinical Translation of Induced Pluripotent Stem Cell‐Derived Blood Cells—Ready for Take‐Off. (26th December 2018)

• Record Type: Journal Article
• Authors: Haake, Kathrin; Ackermann, Mania; Lachmann, Nico
• Is Part Of: Stem cells translational medicine. Volume 8:Number 4(2019)
• Page Start: 332
• Page End: 339
• Publication Date: 2018-12-26
• Subjects: Induced pluripotent stem cells -- Blood -- Macrophages -- Erythrocytes -- Platelets -- Upscaling -- Clinical translation -- GMP; Stem cells -- Periodicals; Regenerative medicine -- Periodicals; Periodicals; 616.0277405
• DOI: 10.1002/sctm.18-0134
• Languages: English
• ISSNs: 2157-6564

Abstract

Abstract: Since their discovery in 2006, induced pluripotent stem cells (iPSCs) have opened up a world of possibilities for regenerative medicine and novel cell‐based therapeutics. Now, over a decade later, robust reprogramming and expansion and differentiation protocols have been developed, and iPSC‐derived cells have been used in a wide variety of small and large animal models to treat many different diseases. Furthermore, the first iPSC derivatives are on their way into clinical trials. In this line, (i) GMP‐compliant generation, cultivation, and differentiation, (ii) preclinical efficacy and safety, as well as (iii) ethical and regulatory compliance of stem cell research represent important aspects that need to be evaluated for proper clinical translation of iPSCs and their derivatives. In this review article, we provide an overview of the current advances and challenges of the clinical translation of iPSC‐derived blood cells and highlight the most pressing problems that have to be overcome in the next years.Stem Cells Translational Medicine 2019;8:332–339 Abstract : Induced pluripotent stem cells (iPSCs) hold great promise for cell‐based therapies. In this concise review, we will provide a brief overview on human iPSC and what bottlenecks have to be addressed prior clinical translation of iPSC‐derived blood cells. The concise review will concentrate on human iPSC generation and will provide latest insights into the differentiation towards hematopoietic stem cells and macrophages under GMP‐compliant conditions.